DOTA-XYIMSR-01
DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy[1].
Product Specifications
CAS Number
2051527-54-7
UNSPSC
12352005
Target
Carbonic Anhydrase
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(NCCOCCOCCNC([C@@H](NC(C[C@@H](C(O)=O)NC(C[C@@H](C(O)=O)NC(CCC(C)(C2=CC=C(O)C=C2)C3=CC=C(O)C=C3)=O)=O)=O)CCCCN4C=C(CCCC(NC5=NN=C(S(=O)(N)=O)S5)=O)N=N4)=O)=O)CC1
Molecular Formula
C61H88N16O22S2
Molecular Weight
1461.58
References & Citations
[1]Wang J, et al. [177Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma. Bioconjug Chem. 2025 Mar 19;36 (3) :588-596.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471081-100 1x 100 µL
CD45RO (190-2F2.5), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680177-100 1x 100 µL
CD50 (ICAM-3) (101-1D2), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471231-100 1x 100 µL
Eosinophil Peroxidase (AHE-1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details